aspirin continuation — Competitive Intelligence Brief

aspirin continuation (aspirin continuation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID. Area: Cardiovascular.

phase 3 NSAID COX Cardiovascular Small molecule

Target snapshot

aspirin continuation (aspirin continuation) — Seoul National University Hospital. Aspirin continuation works by inhibiting the enzyme cyclooxygenase, which is involved in the production of prostaglandins and thromboxanes, leading to a decrease in platelet aggregation and blood clot formation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
aspirin continuation TARGET	aspirin continuation	Seoul National University Hospital	phase 3	NSAID	COX
Celebrex	celecoxib	Pfizer Inc. (originally Searle/Pharmacia)	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	COX-2	1998-12-31
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Diclofenac sodium gel 3%	Diclofenac sodium gel 3%	LEO Pharma	marketed	NSAID (nonsteroidal anti-inflammatory drug)	COX-1 and COX-2 (cyclooxygenase enzymes)
Ibuprofen/acetaminophen	Ibuprofen/acetaminophen	Montefiore Medical Center	marketed	Analgesic/antipyretic combination (NSAID + non-NSAID analgesic)	Cyclooxygenase (COX-1, COX-2) for ibuprofen; prostaglandin synthesis and central pain pathways for acetaminophen
Ibuprofen + Paracetamol + Codeine	Ibuprofen + Paracetamol + Codeine	Ullevaal University Hospital	marketed	Combination analgesic (NSAID + acetaminophen + opioid)	COX-1/COX-2 (ibuprofen, paracetamol); mu opioid receptor (codeine)
Codeine + Diclofenac	Codeine + Diclofenac	University of Sao Paulo	marketed	Opioid + NSAID combination analgesic	Mu opioid receptor (codeine); COX-1 and COX-2 (diclofenac)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2036-05-27 — Celebrex · 10722456 · Formulation · US
• 2036-05-27 — Celebrex · 10799517 · Formulation · US
• 2036-05-27 — Celebrex · 9949990 · Formulation · US
• 2036-05-27 — Celebrex · 9795620 · Formulation · US
• 2036-05-27 — Celebrex · 9572819 · Formulation · US
• 2036-05-27 — Celebrex · 10376527 · Formulation · US

Sponsor landscape (NSAID class)

1. Antibe Therapeutics Inc. · 3 drugs in this class
2. Iroko Pharmaceuticals, LLC · 3 drugs in this class
3. Organon and Co · 2 drugs in this class
4. Apsen Farmaceutica S.A. · 2 drugs in this class
5. Amneal Pharmaceuticals, LLC · 2 drugs in this class
6. Behar, Caren, M.D. · 2 drugs in this class
7. IDEA AG · 2 drugs in this class
8. Noven Pharmaceuticals, Inc. · 2 drugs in this class
9. HALEON · 2 drugs in this class
10. Pfizer · 2 drugs in this class